PriceTargets.com logo

Galecto - GLTO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 57.36%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$6.36 As of 11/15/2024 01:00 AM ET
▼ -0.56 (-8.10%)

This chart shows the closing price for GLTO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galecto Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLTO

Analyst Price Target is $10.00
▲ +57.36% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Galecto in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 57.36% upside from the last price of $6.36.

This chart shows the closing price for GLTO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Galecto. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/17/2024OppenheimerBoost TargetOutperform ➝ Outperform$9.00 ➝ $10.00
6/10/2024OppenheimerLower TargetOutperform ➝ Outperform$250.00 ➝ $225.00
9/28/2023HC WainwrightDowngradeBuy ➝ Neutral
8/21/2023HC WainwrightLower TargetBuy ➝ Buy$300.00 ➝ $50.00
8/15/2023Leerink PartnrsDowngradeOutperform ➝ Market Perform
8/15/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform
8/15/2023Leerink PartnersReiterated RatingOutperform ➝ Market Perform$325.00 ➝ $50.00
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$300.00
8/1/2023OppenheimerReiterated RatingOutperform ➝ Outperform$300.00
6/20/2023OppenheimerInitiated CoverageOutperform
5/15/2023HC WainwrightReiterated RatingBuy
3/17/2023Cantor FitzgeraldInitiated CoverageOverweight$400.00
3/10/2023Credit Suisse GroupReiterated RatingOutperform$150.00
8/3/2022Leerink PartnersLower TargetOutperform$400.00 ➝ $325.00
8/6/2021Credit Suisse GroupLower TargetOutperform$300.00 ➝ $175.00
3/16/2021Credit Suisse GroupLower TargetOutperform$725.00 ➝ $300.00
3/16/2021Leerink PartnersLower TargetOutperform$675.00 ➝ $400.00
11/23/2020Leerink PartnersInitiated CoverageOutperform$675.00
11/23/2020Credit Suisse GroupInitiated CoverageOutperform$725.00
11/23/2020Bank of AmericaInitiated CoverageBuy
(Data available from 11/17/2019 forward)

News Sentiment Rating

-0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Galecto logo
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $6.36
Low: $6.36
High: $6.76

50 Day Range

MA: $9.20
Low: $6.36
High: $14.15

52 Week Range

Now: $6.36
Low: $6.36
High: $23.50

Volume

9,126 shs

Average Volume

16,610 shs

Market Capitalization

$8.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Galecto?

The following sell-side analysts have issued reports on Galecto in the last twelve months: Oppenheimer Holdings Inc..
View the latest analyst ratings for GLTO.

What is the current price target for Galecto?

0 Wall Street analysts have set twelve-month price targets for Galecto in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 57.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting GLTO will reach $10.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $10.00 for Galecto in the next year.
View the latest price targets for GLTO.

What is the current consensus analyst rating for Galecto?

Galecto currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLTO will outperform the market and that investors should add to their positions of Galecto.
View the latest ratings for GLTO.

What other companies compete with Galecto?

Other companies that are similar to Galecto include Liminal BioSciences, Dyadic International, LianBio, Estrella Immunopharma and Passage Bio. Learn More about companies similar to Galecto.

How do I contact Galecto's investor relations team?

Galecto's physical mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The company's listed phone number is 45-7070-5210. The official website for Galecto is galecto.com. Learn More about contacing Galecto investor relations.